Hydrocortisone Hemisuccinate Anhydrous

Hydrocortisone Hemisuccinate Anhydrous

SCHEMBL1320103

C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O.[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR3C1

The experimentally established mechanism targets of Hydrocortisone Hemisuccinate Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 known ✓ P04150 6/20 0.71
HIF1A Q16665 11/20 0.98
SMN1; SMN2 Q16637 3/20 0.98
NFKB1 P19838 2/20 0.84
PMP22 Q01453 1/20 0.84
TSHR P16473 1/20 0.84
MAPT P10636 2/20 0.80
POLB P06746 1/20 0.80
GAA P10253 1/20 0.80
PGR P06401 4/20 0.79
LMNA P02545 3/20 0.79
SERPINA6 P08185 2/20 0.79
AR P10275 2/20 0.79
CHRM1 P11229 2/20 0.79
CYP3A4 P08684 2/20 0.77
FNTA P49354 1/20 0.71
FNTB P49356 1/20 0.71
CYP2C19 P33261 2/20 0.71
HSD17B10 Q99714 2/20 0.71
NR3C2 P08235 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL3360404 1.00 HIF1A (0.98) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL12541145 0.99 HIF1A (1.00) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL7664 0.99 HIF1A (1.00) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL10393928 0.99 HIF1A (1.00) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL12540616 0.99 HIF1A (1.00) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL13960044 0.99 HIF1A (1.00) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL10393930 0.99 HIF1A (1.00) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL22527563 0.98 HIF1A (0.98) HIF1ASMN1; SMN2NFKB1PMP22TSHR
Hydrocortisone Hemisuccinate Anhydrous SCHEMBL7125687 0.97 HIF1A (0.92) HIF1ASMN1; SMN2NFKB1PMP22TSHR
SCHEMBL16018308 0.96 HIF1A (0.93) HIF1ASMN1; SMN2NFKB1PMP22TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834722-B2 Method of testing a gene therapy vector BRUNEL UNIVERSITY LONDON (GB) 2023-12-05 US disclosed
EP-3652347-B1 METHOD OF TESTING A GENE THERAPY VECTOR UNIV BRUNEL (GB) 2023-05-03 EP disclosed
CN-114480253-B Culture medium for directional induced differentiation of pluripotent stem cells into hepatocytes, culture method and application 深圳市三启生物技术有限公司 2023-02-28 CN disclosed
CN-114480495-A Expression method and application of ALB fusion protein 深圳市三启生物技术有限公司 2022-05-13 CN disclosed
CN-114480253-A Culture medium for directional induced differentiation of pluripotent stem cells into hepatocytes, culture method and application 深圳市三启生物技术有限公司 2022-05-13 CN disclosed
US-20210130915-A1 METHOD OF TESTING A GENE THERAPY VECTOR BRUNEL UNIVERSITY LONDON (GB) 2021-05-06 US disclosed
EP-3072507-B1 PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY SHIRE VIROPHARMA LLC (US) 2020-12-23 EP disclosed
EP-3652347-A1 METHOD OF TESTING A GENE THERAPY VECTOR Brunel University London (GB) 2020-05-20 EP disclosed
US-10583146-B2 Pharmaceutical compositions for glucocorticoid replacement therapy SHIRE VIROPHARMA INCORPORATED (US) 2020-03-10 US disclosed
WO-2019012259-A1 METHOD OF TESTING A GENE THERAPY VECTOR BRUNEL UNIVERSITY LONDON (GB) 2019-01-17 WO disclosed
EP-1744760-A2 PHARMACEUTICAL COMPOSITIONS FOR ACUTE GLUCOCORTICOID THERAPY Duocort AB (SE) 2007-01-24 EP disclosed
WO-2005102287-A2 Pharmaceutical compositions for acute glucocorticoid therapy DUOCORT AB (SE) 2005-11-03 WO disclosed
WO-2005102271-A2 PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY DUOCORT AB (SE) 2005-11-03 WO disclosed
US-6878747-B2 Systemic formulations containing beta-carotene and derivatives thereof BARANOWITZ STEVEN A (US) 2005-04-12 US disclosed
EP-1084215-B1 FRACTIONATION PROCESS KARLSHAMNS AB (SE) 2005-01-19 EP disclosed
US-20040068009-A1 Systemic formulations containing beta-carotene and derivatives thereof BARANOWITZ STEVEN A (US) 2004-04-08 US disclosed
US-6552208-B1 Separation of vegetable oils into confectionary fat and product enriched in unsaponifiables KARLSHAMNS AB (SE) 2003-04-22 US disclosed
WO-2002058586-A2 SYSTEMIC FORMULATIONS CONTAINING BETA-CAROTENE AND DERIVATIVES THEREOF BARANOWITZ STEVEN (US) 2002-08-01 WO disclosed
EP-1084215-A1 FRACTIONATION PROCESS Karlshamns AB (SE) 2001-03-21 EP disclosed
WO-1999063031-A1 FRACTIONATION PROCESS KARLSHAMNS AB (SE) 1999-12-09 WO disclosed